It Is Time to End Routine Laboratory Monitoring for Isotretinoin

This Viewpoint describes current evidence regarding adverse events associated with isotretinoin therapy and recommends limiting routine laboratory monitoring for patients receiving the therapy.

Corresponding Author: Joseph C. Pierson, MD, Department of Dermatology, University of Vermont Health, 350 Tilley Dr, Ste 201, South Burlington, VT 05403 (joseph.pierson@uvmhealth.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.